Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story

Journal of Neuroimmunology

Volumn 234, Issue 1-2, 2011, Pages 1-6

  Caminero, Ana ^a,b   Comabella, Manuel ^b   Montalban, Xavier ^b  

^a Sección de Neurología   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anti TNF ; Multiple sclerosis; Proinflammatory cytokines; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REMYELINIZATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955646245     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.03.004     Document Type: Review

References (55)

1. Alexopoulou L., Kranidioti K., Xanthoulea S., Denis M., Kotanidou A., Douni E., Blackshear P.J., Kontoyiannis D.L., Kollias G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 2006, 36:2768-2780.
2. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
3. Atzeni F., Sarzi-Puttini P., Dell'Acqua D., de Portu S., Cecchini G., Cruini C., Carrabba M., Meroni P.L. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther. 2006, 8:R3.
4. Bellesi M., Logullo F., Di Bella P., Provinciali L. CNS demyelination during anti-tumor necrosis factor alpha therapy. J. Neurol. 2006, 253:668-669.
5. Beutler B., Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu. Rev. Immunol. 1989, 7:625-655.
6. Booker M.J., Flint J., Saravana S. Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report. Cases J. 2008, 1:364.
7. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumor. Proc. Natl Acad. Sci. U.S.A. 1975, 72:3666-3670.
8. Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhace the plasticity of the immune system. Cytokine Growth Factor Rev. 2004, 15:353-366.
9. Enayati P.J., Papadakis K.A. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J. Clin. Gastroenterol. 2005, 39:303-306.
10. Foroozan R., Buono L.M., Sergott R.C., Savino P.J. Retrobulbar optic neuritis associated with infliximab. Arch. Ophthalmol. 2002, 120:985-987.
11. Fotin-Mleczek M., Henkler F., Samuel D., Reichwein M., Hausser A., Parmryd I., Scheurich P., Schmid J.A., Wajan H. Apoptotic crosstalk of TNF receptors. TNFR2-induces depletion of TRAF2 and IAP proteins and accelerates NTR-R1-dependent activation of caspase-8. J. Cell Sci. 2002, 115:2757-2770.
12. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
13. Grell M. Tumor necrosis factor (TNF) receptors in cellular signalling of soluble and membrane-expressed TNF. J. Inflamm. 1995, 47:8-17.
14. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
15. Grell M., Wajant H., Zimmermann G., Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Nat. Acad. Sci. U.S.A. 1998, 95:570-575.
16. Gupta G., Gelfand J.M., Lewis J.D. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005, 129:819-826.
17. Hofman F.M., Hinton D.R., Johnson K., Merrill J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 1989, 170:607-612.
18. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 2001, 193:427-434.
19. Kassiotis G., Pasparakis M., Kollias G., Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 1999, 29:774-780.
20. Körner H., Lemcker F.A., Chaudhri G., Etteldorf S., Sedgwick J.D. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. 1997, 27:1973-1981.
21. Körner H., Riminton D.S., Strickland D.H., Lemckert F.A., Pollard J.D., Sedgwick J.D. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 1997, 186:1585-1590.
22. Licastro F., Chiappelli M., Ianni M., Porcellini E. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. Int. J. Immunopathol. Pharmacol. 2009, 22:567-572.
23. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., Braun J., Reed E., Gjertson D., Singh R.R. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 2008, 126:13-30.
24. Magnano M.D., Robinson W.H., Genovese M.C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol. 2004, 22(Suppl. 35):S134-S140.
25. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
26. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45-57.
27. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., Richert J.R., Siegel J.N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44:2862-2869.
28. Pimentel-Muiños F.X., Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999, 11:783-793.
29. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl Acad. Sci. U.S.A. 1995, 92:11294-11298.
30. Ramos-Casals M., Brito-Zeron P., Muñoz S., Soria N., Galiana D., Bertolaccini L., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
31. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Helwig A., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 1995, 37:82-88.
32. Rigby W.F.C. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive aggressive behavior?. Nat. Clin. Pract. Reumatol. 2007, 3:227-233.
33. Ruddle N.H., Bergman C.M., McGrath M.L., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 1990, 172:1193-1200.
34. Ruuls R.M., Hoek R.M., Ngo V.N., McNeil T., Lucian L.A., Janatpour M.J., Körner H., Scheerens H., Hessel E.M., Cyster J.G., McEvoy L.M., Sedgwick J.D. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001, 15:533-543.
35. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 2002, 301:418-426.
36. Selmaj K., Raine C.S., Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 1991, 30:694-700.
37. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 1995, 56:135-141.
38. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991, 325:467-472.
39. Sicotte N.L., Voskuhl R.R. Onset of multiple sclerosis associated with antiTNF therapy. Neurology 2001, 57:1885-1888.
40. Stübgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281-292.
41. Suvannavejh G.C., Lee H.O., Padilla J., Dal Canto M.C., Barret T.A., Miller S.D. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG (35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 2000, 205:24-33.
42. Tanno M., Nakamura I., Kobayashi S., Kurihara K., Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin. Rheumatol. 2006, 25:929-933.
43. Tartaglia L.A., Pennica D., Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 1993, 268:18542-18548.
44. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis GroupUniversity of British Columbia MS/MRI Analysis Group.
45. Thomas C.W., Weinshenker B.G., Sandborn W.J. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Chrohn's disease. Inflamm. Bowel Dis. 2004, 10:28-31.
46. Titelbaum D.S., Degenhardt A., Kinkel R.P. Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am. J. Neuroradiol. 2005, 26:1548-1550.
47. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
48. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
49. Wallach D., Engelmann H., Nophar Y., Aderka D., Kemper O., Hornik V., Holtmann H., Brakebusch C. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991, 5:51-57.
50. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17:331-367.
51. Weiss T., Grell M., Hessabi B., Bourteele S., Müller G., Scheurich P., Wajant H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J. Immunol. 1997, 158:2398-2404.
52. Winkelman A., Patejdl R., Wagner S., Benecke R., Zettl U.K. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J. Neurol. 2008, 255(Suppl. 6):109-114.
53. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Sing R.R. TNFalpha blockade in human diseases: mechanisms and future directions. Clin. Immunol. 2008, 126:121-136.
54. Yang L., Lindholm K., Konishi Y., Li R., Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci. 2002, 22:3025-3032.
55. Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr. Opin. Struct. Biol. 2004, 14:154-160.